Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 14 citing Kim: Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin.... (0.08 sec) 

Thiazolidinediones improve beta-cell function in type 2 diabetic patients

- physiology.org
A Gastaldelli, E Ferrannini, Y Miyazaki, M … - American Journal of Physiology- Endocrinology And …, 2007 - Am Physiological Soc
Thiazolidinediones (TZDs) improve glycemic control and insulin sensitivity in
patients with type 2 diabetes mellitus (T2DM). There is growing evidence from in
vivo and in vitro studies that TZDs improve pancreatic -cell function. The ...
Cited by 39 - Related articles - BL Direct - All 6 versions

Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired …


K Osei, T Gaillard, D Schuster - Metabolism, 2007 - Elsevier
Peripheral insulin levels are determined by beta-cell secretion, insulin
sensitivity, and hepatic insulin extraction (HIE). We have previously shown that
whereas sulfonylureas reduce insulin extraction, metformin enhances HIE. ...
Cited by 8 - Related articles - All 14 versions

Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose …


M González-Ortiz, E Hernández-Salazar, AM … - Diabetes research and clinical practice, 2007 - Elsevier
A randomized, double-blind, placebo-controlled clinical trial was carried out in
18 overweight or obese patients with both impaired fasting glucose and impaired
glucose tolerance. Pharmacological intervention consisted of an oral ...
Cited by 6 - Related articles - All 12 versions

Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice


OJ How, TS Larsen, AD Hafstad, A Khalid, … - Archives of physiology and biochemistry, 2007 - informahealthcare.com
Isolated perfused hearts from type 2 diabetic (db/db) mice show impaired
ventricular function, as well as altered cardiac metabolism. Assessment of the
relationship between myocardial oxygen consumption (MVO 2 ) and ventricular ...
Cited by 6 - Related articles - BL Direct - All 6 versions

Rosiglitazone is more effective than metformin in improving fasting indexes of glucose …


A Brunani, A Caumo, S Graci, G Castagna, G … - Diabetes, Obesity and Metabolism, 2008 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ...
Cited by 1 - Related articles - All 2 versions

Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the …


J Lamontagne, E Pepin, ML Peyot, E Joly, NB … - Endocrinology, 2009 - Endocrine Soc
Thiazolidinediones (TZDs) have beneficial effects on glucose homeostasis via
enhancement of insulin sensitivity and preservation of β-cell function. How
TZDs preserve β-cells is uncertain, but it might involve direct effects ...
Cited by 1 - Related articles - All 4 versions

The Insulin Resistance Syndrome: Concept and Therapeutic Approaches


GM Reaven - … of Diabetes: New Developments: Improving Life and …, 2007 - Springer
Approximately 70 years ago Himsworth and colleagues completed a series of
elegant experiments demonstrating for the first time the importance of insulin
resistance in human disease [1–5]. The results of their experiments ...
Related articles - All 2 versions

Direct rosiglitazone-induced modifications in insulin secretion, action and clearance: a …


A Farret, H Chevassus, B Roux, P Petit, F … - Diabetologia, 2007 - Springer
Abstract Aims/hypothesis In addition to the improvement in insulin sensitivity,
it has been shown that thiazolidinediones modulate beta cell function and
insulin clearance in type 2 diabetic subjects. However, interactions ...
Related articles - BL Direct - All 4 versions

The Dual Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Activator Muraglitazar …

- aspetjournals.org
E Tozzo, R Ponticiello, JA Swartz, D Farrelly … - Journal of Pharmacology and Experimental …, 2007 - ASPET
There are two major defects in type 2 diabetes: 1) insulin resistance and 2)
insulin deficiency due to loss of -cell function. Here we demonstrated that
treatment with muraglitazar (a dual peroxisome proliferator-activated ...
Related articles - All 4 versions

Evaluation of Rosiglitazone Administration on Cardiovascular Function in Severe Obesity


A Brunani, A Liuzzi, AM Titon, S Graci, G … - System, 1927 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ...
Related articles - All 2 versions


Result Page: 

1

2

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google